Thread by @MPishvaian

😀I am so excited to be at my 1⃣st IN PERSON ASCO GI in 3y

✅To prepare, I have gone through the abstract titles, and here are my Top GI ASCO 2023 abstracts

📣Disclaimer: There is no bias or exclusion intended.
These are just the ones I personally want to see👀

#GI23
➡️Starting with #Cholangiocarcinoma because it is a big year - especially because of:
✅SWOG 1815: A phase III trial of gem-cis-nab-pac vs. gem-cis as 1⃣st line💊for advanced BTC
👁️Rachna Shroff, Abs LBA490
@rachnatshroff

#GI23
➡️Two impt ImmunoTx trials:
✅IMbrave151: Phase 2 trial of gem-cis-atezo + /- bev as 1⃣st line💊for advanced BTC
👁️A El-Khoueiry, Abs 491

✅Also a TOPAZ-1 report on the long-term survivors Txed with gem-cis-durva 1⃣st line for advanced BTC
👁️M Bouattour, Abs 531, Pos C1

#GI23
➡️Two🎯💊abstracts for BTC:
✅A TAPUR study update of Pertuz➕trastuz in BTC Pts w/ERBB2/3 alterations
👁️Tim Cannon, Abs 546, Pos C16

✅DDR gene alterations in advanced BTC Pts Txed w/2⃣line BSC +/- FOLFOX (ABC-06 trial)
👁️Angela Lamarca, Abs 593, Pos F5

#GI23
➡️And finally a novel💊trial in advanced BTC
✅A randomized Phase 2 trial of Nanvuranlat, an L-type amino acid transporter (LAT1) inhibitor for Pts w/advanced refractory BTC
👁️Junji Furuse, Abs 494, Pos A3

#GI23
➡️Moving on to #PancreaticCancer and we ACTUALLY have a Late Breaking Abstract (which we were told is a positive study👏)
✅NAPOLI-3: A randomized trial NALIRIFOX (Nal-iri, 5FU, and oxali) vs. gem-nap-pac as 1⃣st line Tx for mPDAC
👁️Zev A. Wainberg, MD, Abs LBA661

#GI23
➡️4⃣practical trials in PDAC:
✅Periop FFX⏩gem-nab-pac for🔪able PDAC
👁️KH Chan, Abs 724, Pos L11

✅Lap cytology for🔪able PDAC
👁️H Tanaka, Abs 674, Pos H18

✅SBRT vs. IMRT4⃣LAPC
👁️ @KarynAGoodman, Abs 713, Pos K20

✅Maint Cape4⃣CRC & PDAC
👁️R Mukherji, Abs 789, Pos M4

#GI23
➡️And3⃣key trials for🧬testing in PDAC:
✅Guideline compliance for🧬testing in PDAC
👁️D Klatte, Abs 688, Pos J13

✅ATM or CHEK2 as biomarkers for iri-based💊 and IO in PDAC
👁️M Mehdi, Abs 754, Pos N1

✅🧬profiling of sarcomatoid PDAC
👁️E Faber, Abs 741, Pos M8

#GI23
➡️Lastly2⃣trials of IO in PDAC:
✅A Phase 2 trial of durva➕SABR for LAPC
👁️@ferguskeane2, Abs 725, Pos L12

✅A Phase I trial of Nivo➕a CCR2/CCR5 dual antagonist (BMS-813160) +/- GVAX for LAPC
👁️E Christenson, Abs 730, Pos L17

#GI23
➡️I'm always a little overwhelmed by #Colorectalcancer - but trying my best:
✅Evaluation of RAS-WT mCRC Pts on the Phase III FIRE-4 trial of FOLFIRI/cetuximab who received the first cycle of treatment with chemotherapy only
👁️Sebastian Stintzing, Abs 100, Pos E17

#GI23
➡️Two more practical updates:
✅The DEEPER trial of FOLFOXIRI➕cetux vs. FOLFOXIRI➕Bev as 1⃣st line Tx for unresectable RAS/RAF WT mCRC
👁️Yu Sunakawa, Abs 120, Pos F17

✅Kinetics of postop cfDNA in Pts with resected stage I-III CRC
👁️Stacey A. Cohen, Abs 5

#GI23
➡️Two trials on non-operative mgmt of rectal Ca:
✅Final surgical salvage results from the OPERA Phase 3
👁️Arthur Sun Myint, Abs 6

✅Organ preservation and TNT for rectal cancer after long-course vs. short-course☢️therapy
👁️Byung Kwan Park, Abs 10, Pos A3

#GI23
➡️Several Ph 1 trials in CRC:
✅Outcomes of pts w/ mCRC in Ph I trials
👁️Ekaterina Ignatova, Abs 142, Pos G20
@postoronnie_

✅A Ph 1a/1b trial of botensilimab, a novel innate/adaptive immune activator➕balstilimab (anti-PD-1 Ab) in MSS mCRC
👁️A El-Khoueiry, Abs LBA8

#GI23
➡️Several Ph 1 trials in CRC:
✅A Ph 1 trial of E7386, a CREB-binding protein/β-cat interaction inh, in pts mCRC
👁️Shunsuke Kondo, Abs 106, Pos F3

✅A Ph II trial of IO w/ CV301, N-803, bintrafusp alfa, and M9241 in pts w/ mCRC
👁️DM Pastor, Abs 116, Pos F13

#GI23
➡️Many TAS-102 trials:
✅TAS-102➕Bev for mCRC: SUNLIGHT study
👁️J Tabernero, Abs 4

✅Panit➕TAS-102 as anti-EGFR rechallenge in RAS WT mCRC: VELO trial
✅S Napolitano, Abs 129, Pos G7

✅Ph Ib trial of PolyPEPI1018 vax➕TAS-102 in MSS mCRC
👁️JM Hubbard, Abs 147, Pos H6

#GI23
➡️And one last IO +☢️therapy trial:
✅Durva➕treme➕ plus local tumor ablation (RFA or SBRT) for mCRC: EORTC-1560-GITCG (ILOC) Phase II
👁️Jenny F. Seligmann, Abs 141, Pos G19

#GI23
(Sorry - had to take a break)
➡️This is a big year for Upper GI Ca too with the positive, practice changing (❓) Ph 3 SPOTLIGHT trial:
✅Zolbetuximab + mFOLFOX6 as 1⃣st-line Tx for claudin-18.2+/ HER2− advanced gastric/GEJ adenoca
👁️Kohei Shitara, LBA292
@KoheiShitara

#GI23
➡️Another important Ph3 trial is Rationale 305:
✅Chemothreapy +/- tislelizumab as 1⃣st-line Tx for advanced gastric/GEJ adenoca
👁️Markus H. Moehler, Abs 286

#GI23
➡️👀forward to 2 dual ICI trials for gastric/GEJ adenoca:
✅INFINITY: A Ph 2 trial of durva➕treme as neoadj Tx for MSI-H🔪able disease:
👁️F Pietrantonio, Abs 358, Pos B15

✅Ph 2 trial of durva➕treme➕paclitaxel as 2⃣nd-line Tx for mGastric Ca
👁️KW Lee, Abs 401, Pos H4

#GI23
➡️A novel HER-2🎯💊 for gastric/GEJ adenoca:
✅HERIZON: A Ph 2 trial of HER-Vaxx (IMU-131), a HER2-targeting peptide vaccine, plus chemo for Pts w/ HER2➕gastric/GEJ adenoca
👀Tanuj Chawla, Abs 289

#GI23
➡️Finally, an exciting platform trial, and a novel💊trial:
✅Neo-AEGIS (Neoadjuvant Trial Esoph/GEJ Ca)
👁️MA Lowery, Abs 295

✅Bintrafusp alfa➕paclitaxel for mGastric Ca as 2⃣nd-line Tx
👁️CK Lee, Abs 374, Pos F15